Business Wire Feed
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi Arabia to support physicians and more...
Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the more...
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD more...
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three years in AMPLIFY Phase III trialWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination more...
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands Genentech’s fixed-duration portfolio by providing eligible first-line patients another option alongside more...
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard-of-care endocrine therapy plus more...
Glen Cove Hospital Earns Presidential Quality Award
First New York hospital to receive Malcolm Baldrige National Quality Award for performance excellence in health careGLEN COVE, N.Y.--(BUSINESS WIRE)--Northwell’s Glen Cove Hospital has earned the Malcolm Baldrige National Quality Award, which recognizes performance excellence more...
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando, FL Presentation on more...
Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company focused on improving patient safety and clinical outcomes, today announced an upcoming Continuing Education webinar to be more...
Owlet to Report Fourth Quarter and Full Year 2025 Financial Results on March 5, 2026
LEHI, Utah--(BUSINESS WIRE)--$owlt #babymonitor--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, plans to announce fourth quarter and full year 2025 financial results after market close on Thursday, March 5, more...
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced more...
Groundbreaking Clinical Study Reveals Promising Evidence for VIVAZEN®’s Kratom Extracts
Findings unveiled at the University of Florida Scientific Kratom Symposium highlight encouraging results for adult use of low-dose proprietary kratom extractsPHOENIX--(BUSINESS WIRE)--VIVAZEN® proudly announces the results of a pioneering 28-day clinical study evaluating the safety more...
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
Integrated analysis of systemic inflammation and tumor immune features identifies biologically distinct patient subgroups with differential survival outcomes, outperforming conventional biomarkers LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #AACRIO26--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new more...
Decorated Senior Army Officer Tal Sullivan Joins Battelle
COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle announced today that Tal Sullivan, a highly decorated retired U.S. Army Special Forces (Green Beret) Colonel with more than 30 years of military and leadership experience, has joined the organization as Senior more...
Concord Technologies Celebrates 30 Years of Innovation and Leadership
Company empowers healthcare organizations by creating a smarter, faster, and more connected information ecosystem, achieving true interoperability and enhancing care deliverySEATTLE--(BUSINESS WIRE)--Concord Technologies, a leading provider of Secure Document Exchange, Intelligent Document Processing, and Interoperability more...
Animate Biosciences Reports Preclinical Data Showing Dramatic Reduction in Cardiac Scarring and Near-Doubling of Heart Function After Experimental Heart Attack
Single-dose designed peptide drives structural and functional cardiac repair in a mouse myocardial infarction modelSAN FRANCISCO--(BUSINESS WIRE)--Animate Biosciences, a biotechnology company focused on designing innovative peptide therapeutics, today announces positive preclinical results demonstrating that its more...
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Designations provide market exclusivity as well as other development incentivesBOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into more...
Chronilogix Integrates with Balance for Life to Expand AI-Driven Behavioral Health and Chronic Care Support
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Chronilogix, a digital health company delivering AI-powered coaching for behavioral health and chronic condition management, announced today a new integration with Balance for Life, a wellness and mental health application serving more...
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly more...
Element Biosciences Introduces VITARI™, Redefining What High-Throughput Sequencing Makes Possible
VITARI will begin shipping in the second half of 2026, with pre-orders now open and early customer commitments already securedSAN DIEGO--(BUSINESS WIRE)--Element Biosciences Inc. today announced VITARI, the first ever high-throughput benchtop sequencing system capable more...
Dock Health Introduces Its Productivity Platform at Mayo Clinic to Modernize Operational Workflows
Dock automates referral processes by streamlining intake, gathering patient history, and improving tracking and outside record requests, accelerating speed time from order to appointmentGREAT BARRINGTON, Mass.--(BUSINESS WIRE)--Dock Health today announced that its productivity platform has more...
NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis
MALVERN, Pa.--(BUSINESS WIRE)--NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared NexEos’s Investigational New Drug more...
Havah Therapeutics to Present at the RiseUp For Breast Cancer and Women’s Health Conference
Presentation to showcase a first-of-its-kind, mechanism-driven approach to breast cancer treatment through targeted androgen receptor (AR) agonism with HAV-088 — built on a fully integrated chain of evidence that connects drug exposure to cellular biology, more...
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Second season results from the Phase 3 SMART trial were presented at the 9th RSVVW Conference and will be shared with the U.S. FDA and other regulatory authoritiesRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as more...
Sunnybrook Receives $10M Gift to Expand OCD Research, Education, and Treatment
The transformational gift from Brian Reeve will propel and accelerate the next phase of growth for the Frederick W. Thompson Anxiety Disorders CentreTORONTO--(BUSINESS WIRE)--Sunnybrook Health Sciences Centre, a national leader in obsessive-compulsive disorder (OCD) care more...